Home › Peripheral Nerve Disorders › NCT07596030
Self-applied taVNS for CIPN
Feasibility of Self-Applied Vagus Nerve Stimulation for Chemotherapy Induced Peripheral Neuropathy
Who can join
Ages 18 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: Chemotherapy-induced peripheral neuropathy (CIPN) group: * Age 18-80 years * Prior exposure to platinum or taxane chemotherapy * Glove/stocking dysesthesias ≥3 months that began after neurotoxic chemotherapy * Worst CIPN-related pain ≥4/10 over the last week Registry Cohort: * Age 18-80 years * Prior exposure to platinum or taxane chemotherapy * Denis any current neuropathic symptoms as described above. Exclusion Criteria: All participants: * Unstable cardiac disease/ Known arrhythmias * Head or neck cancer or metastases * Recent ear trauma or active dermatologic disease at the stimulation site * \<2 months since completion of cancer treatment or surgery * Metal implants in the head or neck (e.g., cochlear implant) * Implanted electronic devices (e.g., pacemaker) * Known allergy to tape/adhesives * History of seizure/epilepsy, intracranial pathology, or skull defect * Pregnancy
About the study
The purpose of this study is to determine the feasibility of using a portable device at home to self-administer transcutaneous auricular vagus nerve stimulation (taVNS). This handheld device has two small electrodes that are placed on specific areas of the outer ear. This device delivers a mild electrical stimulation to the vagus nerve through the ear. This study will explore how taVNS may affect symptoms of chemotherapy-induced peripheral neuropathy (CIPN). Participants will be assigned to one of two cohorts based on the presence of chemotherapy-induced peripheral neuropathy (CIPN). Participants with CIPN will be placed in the intervention cohort (n=24) and will complete a 2-week trial of daily self-applied taVNS. Participants without CIPN will be placed in the registry cohort (n=12) and will complete study measurements without receiving the intervention. The registry cohort will not receive the taVNS intervention but will undergo identical physiological assessments at baseline and at a 2 week follow up to control for testing effects and biological variability.
What is being tested
- Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) (device)
Sponsor: University of Miami · Participants: 36 · Started: Jun 2, 2026
Contact the study team
- Richard L Martinez, MSPH · Phone: 3052842359
- Marlon L Wong, PT, PhD · Phone: 3052842670
Official record on ClinicalTrials.gov — NCT07596030
Locations in the U.S.
| Florida | University of Miami, Plumer Building, Coral Gables |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.